Tevogen Bio develops T cell therapy to target HPV in women with precancerous cervical lesions
Summary: Tevogen Bio is advancing its development of TVGN 920, a T cell therapy aimed at treating human papillomavirus (HPV) in women with precancerous cervical lesions. This therapy uses genetically unmodified T cells to target HPV, which is linked to cervical cancer.
Currently, about one in three women remain HPV positive after treatment for high-grade cervical lesions, increasing the risk of recurrence and cancer. Tevogen's new approach seeks to eradicate HPV, potentially preventing both recurrent lesions and the spread of the virus.
The investigational therapy will undergo safety and feasibility studies using Tevogen's ExacTcell technology. The company aims to address significant public health concerns related to HPV and its association with cervical cancer.
This is article metrics. Combined, they form a significance score, that indicates how important the news is on a scale from 0 to 10.
My algorithm scores 10,000 news articles daily, and creates a single significance-ordered list of news.
Read more about how I calculate significance, or see today's top ranked news on the main page:
See today's news rankings